{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:56Z","timestamp":1790155736352,"version":"4.0.1"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T00:00:00Z","timestamp":1362441600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0057631","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T17:31:27Z","timestamp":1362504687000},"page":"e57631","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":46,"title":["Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients"],"prefix":"10.1371","volume":"8","author":[{"given":"Brandy","family":"Young-Gqamana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastry","family":"Brignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hwa","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richie","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Soska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela A.","family":"Sitaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Boudes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Valenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfrida R.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Desnick R, Ioannou Y, Eng C (2001) \u03b1-Galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York, New York, USA: McGraw-Hill. 3733\u20133774.","DOI":"10.1006\/rwgn.2001.0443"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-007-0468-6","article-title":"Cellular and tissue localization of globotriaosylceramide in Fabry disease","volume":"451","author":"H Askari","year":"2007","journal-title":"Virchows Arch"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry&apos;s disease: ceramide trihexosidase deficiency","volume":"276","author":"OR Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"PC3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Fabry&apos;s disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid","volume":"238","author":"CC Sweeley","year":"1963","journal-title":"J Biol Chem"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis doi:10.1186\/1750-1172-5-30.","DOI":"10.1186\/1750-1172-5-30"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry","volume":"93","author":"WR Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry&apos;s disease with manifestations confined to the myocardium","volume":"324","author":"W von Scheidt","year":"1991","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"JM Aerts","year":"2008","journal-title":"Proc Nat Acad Sci USA"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"SM Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"T Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry&apos;s disease","volume":"345","author":"CM Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1651-2227.2008.00649.x","article-title":"Early therapeutic intervention in females with Fabry disease?","volume":"97","author":"DA Hughes","year":"2008","journal-title":"Acta Paediatr"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"R Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"R Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"M West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase \u03b2 treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"DG Warnock","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"MJ van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Rombach SM, Aerts JMFG, Poorthuis BJ, Groener JEM, Donker-Koopman WE, <etal>et al<\/etal>.. (2012) Long-term effect of antibodies against infused \u03b1-galactosidase A in Fabry disease on plasma and urinary lyso-Gb<sub>3<\/sub> reduction and treatment outcome. PLoS ONE 7(10) doi:10.1371\/journal.pone.0047805.","DOI":"10.1371\/journal.pone.0047805"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0076-6879(03)01069-3","article-title":"Cell-based screening of active-site specific chaperone for the treatment of Fabry disease","volume":"363","author":"J-Q Fan","year":"2003","journal-title":"Methods Enzymol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"J-Q Fan","year":"1999","journal-title":"Nature Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders","volume":"9","author":"KJ Valenzano","year":"2011","journal-title":"Assay Drug Dev Technol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"GH Yam","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"GH Yam","year":"2005","journal-title":"FASEB J"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/jpet.108.149054","article-title":"Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease","volume":"328","author":"S Ishii","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"R Khanna","year":"2010","journal-title":"Mol Ther"},{"key":"ref26","unstructured":"Germain DP, Giugliani R, Hughes DA, Mehta A, Nicholls K, <etal>et al<\/etal>.. (2012) Safety and pharmacodynamic effects of the pharmacological chaperone migalastat hydrochloride on \u03b1-galactosidase A activity and globotriosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis 7: 91. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ojrd.com\/content\/7\/1\/91\" xlink:type=\"simple\">http:\/\/www.ojrd.com\/content\/7\/1\/91<\/ext-link> Accessed 2013 Jan 17."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb<sub>3<\/sub> function as a biomarker in Fabry disease?","volume":"411","author":"C Auray-Blais","year":"2010","journal-title":"Clin Chim Acta"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"T Ohshima","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"ER Benjamin","year":"2012","journal-title":"Mol Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of \u03b1-galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"YA Ioannou","year":"2001","journal-title":"Am J Hum Genet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2010.08.006","article-title":"Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease","volume":"399","author":"T Togawa","year":"2010","journal-title":"Biochem Biophys Res Comm"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"N Asano","year":"2000","journal-title":"Eur J Biochem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases \u03b1-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"E Benjamin","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","article-title":"Screening for pharmacological chaperones in Fabry disease","volume":"359","author":"S-H Shin","year":"2007","journal-title":"Biochem Biophys Res Comm"},{"key":"ref35","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"DP Germain","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jchromb.2011.11.020","article-title":"Quantification of the Fabry marker lyso-Gb<sub>3<\/sub> in human plasma by tandem mass spectrometry","volume":"883\u2013884","author":"R Kr\u00fcger","year":"2012","journal-title":"Journal of Chromatography B"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"WR Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Novel urinary lyso-Gb<sub>3<\/sub>-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"C Auray-Blais","year":"2012","journal-title":"Anal Chem"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Boutin M, Gagnon R, Lavoie P, Auray-Blais C (2012) LC\u2013MS\/MS analysis of plasma lyso-Gb3 in Fabry disease [published online ahead of print October 2, 2012]. Clin Chim Act doi: 10.1016\/j.cca.2012.09.026.","DOI":"10.1016\/j.cca.2012.09.026"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"X Wu","year":"2011","journal-title":"Human Mutat"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"C Auray-Blais","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000185286","article-title":"Verotoxin receptor glycolipid in human renal tissue","volume":"51","author":"B Boyd","year":"1989","journal-title":"Nephron"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1194\/jlr.M017178","article-title":"Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice","volume":"52","author":"B Durant","year":"2011","journal-title":"J Lipid Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-2275(20)42254-0","article-title":"Lipid composition of lysosomal multilamellar bodies of male mouse urine","volume":"32","author":"SK Gross","year":"1991","journal-title":"J Lipid Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1210\/endo-113-1-251","article-title":"Testosterone-responsive mouse kidney glycosphingolipids: developmental and inbred strain effects","volume":"113","author":"RH McCluer","year":"1983","journal-title":"Endocrinology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"13112","DOI":"10.1016\/S0021-9258(18)43014-1","article-title":"Testosterone effects on the induction and urinary excretion of mouse kidney glycosphingolipids associated with lysosomes","volume":"256","author":"RH McCluer","year":"1981","journal-title":"J Biol Chem"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.0537900100","article-title":"Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer","volume":"100","author":"J Park","year":"2003","journal-title":"Proc Nat Acad Sci USA"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2008.10.017","article-title":"Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period","volume":"96","author":"K Ogawa","year":"2009","journal-title":"Mol Genet Metab"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"T Ohshima","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1073\/pnas.120177997","article-title":"Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells","volume":"97","author":"T Takenaka","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10545-011-9308-6","article-title":"Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies","volume":"34","author":"J Aerts","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/187152506778520718","article-title":"The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature","volume":"4","author":"S Bekri","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Young E, Mills K, Morris P, Vellodi A, Lee P, <etal>et al<\/etal>.. (2005) Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr 94: 51\u201354; discussion 37\u201358.","DOI":"10.1080\/08035320510028111"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0057631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T23:53:27Z","timestamp":1644450807000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0057631"}},"subtitle":[],"editor":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,5]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0057631","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,5]]}}}